Irinotecan in combined-modality therapy for locally advanced non-small-cell lung cancer

ONCOLOGY

Volumn 15, Issue 1 SUPPL. 1, 2001, Pages 31-36

  Choy, Hak ^a   Macrae, Rob ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; IRINOTECAN;

HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MULTIMODALITY CANCER THERAPY; REVIEW; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; SURVIVAL RATE;

EID: 0035222087     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Greenlee RT, Murray T, Beiden S, et al: Cancer statistics, 2000. CA Cancer J Clin 50(1):7-33, 2000.
2. Stevens CW, Lee JS, Cox J, et al: Novel approaches to locally advanced unresectable non-small cell lung cancer. Radiother Oncol 55(1): 11-18, 2000.
3. Steele GG, Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity. Int J Radiat Oncol Biol Phys 5:85-91, 1979.
4. Dillman RO, Hemdon J, Seagren SL, et al: Improved survival in stage III non-small-cell lung cancer: Seven year follow up of Cancer and Leukemia Group B 8433 trial. J Natl Cancer Inst 88:1210-1215, 1996.
5. Schaakae-Koning C, Vanden Bogart W, Dalesio O: Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 326:524-530, 1992.
6. Sause WT, Scott C, Taylor S, et al: Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small cell lung cancer. J Natl Cancer Inst 87:198-205, 1995.
7. LeChevalier T, Arriagada R, Quoix E, et al: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-smallcell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417-423, 1991.
8. Pritchard RS, Anthony SP: Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small cell lung cancer. A meta-analysis. Ann Intern Med 125:723-729, 1996.
9. Hsiang Y-H, Hertzberg R, Hecht S, et al: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase 1. J Biol Chem 260:14873-14878, 1985.
10. Hsiang Y-H, Liu LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722-1726, 1988.
11. Andoh T, Ishii K, Suzuki Y, et al: Characterization of a mammalian mutant with a camptothecin resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84:5565-5569, 1987.
12. Nitiss J, Wang JC: DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Nail Acad Sci USA 85:7501-7505, 1988.